Acute Lymphocytic Leukemia – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline Review, H2 2020’, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

– The report reviews pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) therapeutics and enlists all their major and minor projects

– The report assesses Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

AbbVie Inc

Actinium Pharmaceuticals Inc

ADC Therapeutics SA

Adlai Nortye Biopharma Co Ltd

Aeglea BioTherapeutics Inc

AIkido Pharma Inc

Aileron Therapeutics Inc

AIMM Therapeutics BV

Aleta Biotherapeutics Inc

Allterum Therapeutics LLC

Amgen Inc

Angiocrine Bioscience Inc

Anhui Anke Biotechnology (Group) Co Ltd

Apexian Pharmaceuticals Inc

Applied Therapeutics Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

AUM Biosciences Pte Ltd

Autolus Therapeutics Plc

Avalon GloboCare Corp

AVM Biotechnology LLC

Ayala Pharmaceuticals Inc

Beam Therapeutics Inc

Beijing Immunochina Pharmaceuticals Co Ltd

Bellicum Pharmaceuticals Inc

Bio-Cancer Treatment International Ltd

Bio-Path Holdings Inc

Bioceltech Therapeutics Ltd

Biocure Technology Inc

BioSight Ltd

Bristol-Myers Squibb Co

Cambridge Innovation Technologies Consulting Ltd

CanBas Co Ltd

Caribou Biosciences Inc

CARsgen Therapeutics Ltd

CASI Pharmaceuticals Inc

Cellectis SA

Cellestia Biotech AG

Cellipse SAS

Cellular Biomedicine Group Inc

Celularity Inc

China Immunotech (Beijing) Biotechnology Co Ltd

China Immunotech Co Ltd

Chongqing Precision Biotech Co Ltd

CoImmune Inc

ConverGene LLC

Cyclacel Pharmaceuticals Inc

Cyteir Therapeutics Inc

Daiichi Sankyo Co Ltd

Delta-Fly Pharma Inc

DevaCell Inc

Dialectic Therapeutics Inc

Diazon Pharmaceuticals Inc

DiNonA Inc

Elf Zone Inc

Enzyme by Design Inc

Epizyme Inc

ERYTECH Pharma SA

Eureka Therapeutics Inc

Evive Biotech

ExCellThera Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Felicitex Therapeutics Inc

Fusion Pharma LLC

Gamida Cell Ltd

GEMoaB Monoclonals GmbH

Generium

Genexine Inc

Gilead Sciences Inc

Gmax Biopharm Ltd

Gracell Biotechnology Ltd

GT Biopharma Inc

Guangzhou Bio-gene Technology Co Ltd

Hangzhou Minsheng Pharmaceutical Group Co Ltd

Hebei Senlang Biotechnology Inc Ltd

HemoGenyx Pharmaceuticals Plc

Henan Honghui Biotechnology Co Ltd

HighPass Bio Inc

Hillstream BioPharma Inc

Housey Pharmaceutical Research Laboratories LLC

HRAIN Biotechnology Co Ltd

Humanigen Inc

Hummingbird Bioscience Pte Ltd

Hunan Siweikang Therapeutics Ltd

iCell Gene Therapeutics LLC

iDD biotech SAS

Iksuda Therapeutics Ltd

ImCheck Therapeutics SAS

ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

ImmunityBio Inc

ImmunoGen Inc

Immunotech Biopharm Ltd

IN8bio Inc

Inatherys

Incuron LLC

Incyte Corp

Innovative Cellular Therapeutics Co Ltd

Interprotein Corp

Jazz Pharmaceuticals Plc

Johnson & Johnson

Juno Therapeutics Inc

Juventas Cell Therapy Ltd

Karyopharm Therapeutics Inc

Kecellitics Biotech Co Ltd

Kenjockety Biotechnology Inc

Kiromic BioPharma Inc

Kronos Bio Inc

Kuur Therapeutics Ltd

Legend Biotech Corp

LegoChem Biosciences Inc

Les Laboratoires Servier SAS

Light Chain Bioscience

Lin Bioscience Inc

MAA Laboratories Inc

MacroGenics Inc

Magenta Therapeutics Inc

Mana Therapeutics Inc

MannKind Corp

ManysmarT Therapeutics Inc

Marker Therapeutics Inc

MediGene AG

Medivir AB

MedPacto Inc

Merck & Co Inc

Meryx Inc

Millennium Pharmaceuticals Inc

Miltenyi Biotec BV & Co KG

Molecular Templates Inc

Nabriva Therapeutics Plc

Nanjing Bioheng Biotech Co Ltd

Nanjing Iaso Biotherapeutics Co Ltd

Nanjing KAEDI Biotech Inc

Nanovalent Pharmaceuticals Inc

NantKwest Inc

Neurotrope Bioscience Inc

Nimbus Therapeutics LLC

Nkarta Inc

Nohla Therapeutics Inc

Novartis AG

NovoMedix LLC

Omeros Corp

Oncoceutics Inc

Onconova Therapeutics Inc

OncoSynergy Inc

OncoTartis Inc

OncoTherapy Science Inc

OneChain Immunotherapeutics

Orca Biosystems Inc

Pascal Biosciences Inc

PentixaPharm GmbH

PeproMene Bio Inc

PersonGen Biomedicine Suzhou Co Ltd

PersonGen BioTherapeutics Suzhou Co Ltd

Pfenex Inc

Pfizer Inc

Pharma Mar SA

PharmaEssentia Corp

Pinotbio Inc

Precision Biosciences Inc

PTC Therapeutics Inc

Regenacy Pharmaceuticals LLC

Regeneron Pharmaceuticals Inc

Retrotherapy LLC

Ryvu Therapeutics SA

Sanofi

Sareum Holdings Plc

SciTech Development LLC

SELLAS Life Sciences Group Inc

Shanghai Bioray Laboratory Inc

Shanghai GeneChem Co Ltd

Shanghai Longyao Biotechnology Inc Ltd

Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd

Shanghai YaKe Biotechnology Inc

Shenzhen BinDeBio Ltd

Sian Wuhan Medical Technology Co Ltd

SpecificiT Pharma Inc

Spectrum Pharmaceuticals Inc

Sumitomo Dainippon Pharma Oncology, Inc

Sun Pharma Advanced Research Company Ltd

Sunnycell Therapeutics Ltd

SunRock Biopharma SL

Syndax Pharmaceuticals Inc

SYNIMMUNE GmbH

Tacitus Therapeutics Inc

Takara Bio Inc

Takeda Pharmaceutical Co Ltd

TC BioPharm Ltd

TCR2 Therapeutics Inc

TheraPharm Deutschland GmbH

Tianjin Mycure Medical Technology Co Ltd

TotalClarity Inc

Trillium Therapeutics Inc

Triphase Accelerator Corp

TScan Therapeutics Inc

UWELL Biopharma Inc

VelosBio Inc

Vincera Pharma Inc

VioQuest Pharmaceuticals Inc (Inactive)

Vor BioPharma Inc

Wugen Inc

Wuhan Bio-Raid Biotechnology Co Ltd

Xbrane Biopharma AB

Xencor Inc

Zhejiang Teruisi Pharmaceutical Co Ltd

Zhuobo Yong Ji (Shanghai) Biological Pharmaceutical Co Ltd

ZIOPHARM Oncology Inc

Zovis Pharmaceuticals

Table of Contents

Table of Contents

Introduction

Acute Lymphocytic Leukemia- Overview

Acute Lymphocytic Leukemia- Therapeutics Development

Acute Lymphocytic Leukemia- Therapeutics Assessment

Acute Lymphocytic Leukemia- Companies Involved in Therapeutics Development

Acute Lymphocytic Leukemia- Drug Profiles

Acute Lymphocytic Leukemia- Dormant Projects

Acute Lymphocytic Leukemia- Discontinued Products

Acute Lymphocytic Leukemia- Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by 4SC AG, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by AbbVie Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Actinium Pharmaceuticals Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by ADC Therapeutics SA, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Aeglea BioTherapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by AIkido Pharma Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Aileron Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by AIMM Therapeutics BV, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Aleta Biotherapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Allterum Therapeutics LLC, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Amgen Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Angiocrine Bioscience Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Apexian Pharmaceuticals Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Applied Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by AstraZeneca Plc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Atara Biotherapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by AUM Biosciences Pte Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Autolus Therapeutics Plc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Avalon GloboCare Corp, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by AVM Biotechnology LLC, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Ayala Pharmaceuticals Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Beam Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Beijing Immunochina Pharmaceuticals Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bellicum Pharmaceuticals Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bio-Cancer Treatment International Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bio-Path Holdings Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bioceltech Therapeutics Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Biocure Technology Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by BioSight Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Bristol-Myers Squibb Co, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cambridge Innovation Technologies Consulting Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by CanBas Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Caribou Biosciences Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by CARsgen Therapeutics Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by CASI Pharmaceuticals Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cellectis SA, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cellestia Biotech AG, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cellipse SAS, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cellular Biomedicine Group Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Celularity Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by China Immunotech (Beijing) Biotechnology Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by China Immunotech Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Chongqing Precision Biotech Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by CoImmune Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by ConverGene LLC, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Cyteir Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Daiichi Sankyo Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Delta-Fly Pharma Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by DevaCell Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Dialectic Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Diazon Pharmaceuticals Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by DiNonA Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Elf Zone Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Enzyme by Design Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Epizyme Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by ERYTECH Pharma SA, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Eureka Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Evive Biotech, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by ExCellThera Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Fate Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Felicitex Therapeutics Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Fusion Pharma LLC, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Gamida Cell Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by GEMoaB Monoclonals GmbH, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Generium, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Genexine Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Gilead Sciences Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Gmax Biopharm Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Gracell Biotechnology Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by GT Biopharma Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Guangzhou Bio-gene Technology Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Hangzhou Minsheng Pharmaceutical Group Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Hebei Senlang Biotechnology Inc Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by HemoGenyx Pharmaceuticals Plc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Henan Honghui Biotechnology Co Ltd, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by HighPass Bio Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Hillstream BioPharma Inc, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline by Zovis Pharmaceuticals, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Dormant Projects, H2 2020

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports